- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
NPPA fixes price of 45 medicine packs
New Delhi: The National Pharmaceutical Pricing Authority (NPPA) has fixed the price of 45 formulation packs including those used for treating cancer, epilepsy, heartburn, eczema and bacterial infections.
"NPPA has fixed / revised the prices in respect of 45 formulation packs under Drug Prices Control Order (DPCO) 2013," the regulator said in a notification on its website.
The companies whose drugs are included for price fixation includes drug majors such as erstwhile Ranbaxy (now Sun Pharmaceutical Industries), Torrent Pharmaceuticals, Abbott Healthcare, Glenmark and Cadila Healthcare, it added.
"The manufacturer or marketing company not complying with the retail prices and conditions specified in notes herein above from the date of this order/notification, shall be liable to deposit overcharged amount along with the interest under the provisions of the DPCO, 1995 read with the Essential Commodities Act, 1955," NPPA said.
NPPA's mandate is to fix/ revise the prices of controlled bulk drugs and formulations and to enforce prices and availability of the medicines in the country.
It also monitors the prices of decontrolled drugs in order to keep them at reasonable levels.
"NPPA has fixed / revised the prices in respect of 45 formulation packs under Drug Prices Control Order (DPCO) 2013," the regulator said in a notification on its website.
The companies whose drugs are included for price fixation includes drug majors such as erstwhile Ranbaxy (now Sun Pharmaceutical Industries), Torrent Pharmaceuticals, Abbott Healthcare, Glenmark and Cadila Healthcare, it added.
"The manufacturer or marketing company not complying with the retail prices and conditions specified in notes herein above from the date of this order/notification, shall be liable to deposit overcharged amount along with the interest under the provisions of the DPCO, 1995 read with the Essential Commodities Act, 1955," NPPA said.
NPPA's mandate is to fix/ revise the prices of controlled bulk drugs and formulations and to enforce prices and availability of the medicines in the country.
It also monitors the prices of decontrolled drugs in order to keep them at reasonable levels.
Next Story